It is now offered in rehabilitative facilities, infusion centers, and wellness spas, making it accessible to patients requiring medical management as well as those seeking wellness benefits
Nang tc cng c chu k vng i ring ca chng
Stop your medication and contact your healthcare provider as soon as possible
Overexpression of lncRNA MEG3 plays an anti-inflammatory effect by regulating the AKT/mTOR signaling pathway (258)
falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseasesSalmonella (typhoid + paratyphoid A)Phase I AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity drivenFrontotemporal dementia with progranulin gene mutationPhase III 26assets ZanubrutinibBTK / Inhibitor / Hematologic Malignancies / Immunology & InflammationTreatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Waldenstrm Macroglobulinemia and Treatment-Nave Waldenstrm MacroglobulinemiaApproved SonrotoclaxBCL2 / Inhibitor / Hematologic MalignanciesTreatment-Naive Chronic Lymphocytic LeukemiaPhase 3Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaApproved TislelizumabPD-1 / Monoclonal Antibody / Lung Cancers / Gastrointestinal Cancers / Other CancersFirst-Line Extensive-Stage Small Cell Lung CancerApprovedFirst-Line Non-Squamous Non-Small Cell Lung CancerApprovedFirst-Line Squamous Non-Small Cell Lung CancerApproved BGB-16673BTK Chimeric Degradation Activation Compound [CDAC] / Hematologic Malignancies / Immunology & InflammationRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Mantle Cell LymphomaPhase 2 BlinatumomabCD19 x CD3 / BiTE [Bispecific T-Cell Engager] / Hematologic MalignanciesRelapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (subcutaneous formulation)Phase 2 TarlatamabDLL3 x CD3 / BiTE [Bispecific T-cell Engager] / Lung CancersFirst-Line Extensive-Stage Small Cell Lung CancerPhase 3First-Line Extensive-Stage Small Cell Lung CancerPhase 3Second-Line Small Cell Lung CancerPhase 3 ZanidatamabHER2 Bispecific / Antibody / Gastrointestinal CancersFirst-Line HER2 Positive Gastroesophageal AdenocarcinomaPhase 3Second-Line HER2 Positive Biliary Tract CancerApprovedFirst-Line HER2 positive Biliary Tract CancerPhase 3 BG-68501CDK2 / Inhibitor / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BGB-21447BCL2 / Inhibitor / Breast/Gynecologic CancersHormone Receptor Positive Breast CancerPhase 1 BGB-43395CDK4 / Inhibitor / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BGB-B455Claudin 6 x CD3 Bispecific / Antibody / Breast/Gynecologic CancersGynecologic and Solid TumorsPhase 1 BG-C9074B7-H4 Antibody Drug Conjugate / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BG-75202KAT6A/B / Inhibitor / Breast/Gynecologic CancersBreast CancerPhase 1 BG-75098CDK2 Chimeric Degradation Activation Compound [CDAC] / Breast/Gynecologic CancersBreast CancerPhase 1 BGB-B2033GPC3 x 4-1BB Bispecific / Antibody / Gastrointestinal CancersSolid TumorsPhase 1 BG-C137FGFR2b Antibody Drug Conjugate / Gastrointestinal CancersGastrointestinal CancersPhase 1 BGB-53038Pan-KRAS / Inhibitor / Gastrointestinal CancersLung Cancers and GI CancersPhase 1 BG-C477CEA Antibody Drug Conjugate / Gastrointestinal CancersLung Cancers and GI CancersPhase 1 BG-C0902EGFR x MET x MET Antibody Drug Conjugate / Lung CancersLung Cancers and GI CancersPhase 1 BG-T187EGFR x MET x MET Trispecific / Antibody / Lung CancersLung Cancers and GI CancersPhase 1 BGB-58067MTA Cooperative PRMT5 / Inhibitor / Lung CancersLung Cancers and GI CancersPhase 1 BG-89894MAT2A / Inhibitor / Lung CancersLung Cancers and Solid TumorsPhase 1 BG-60366EGFR Chimeric Degradation Activation Compound [CDAC] / Lung CancersLung CancersPhase 1 BGB-26808HPK1 / Inhibitor / Gastrointestinal CancersSolid Tumors/Pan- TumorPhase 1 XaluritamigSTEAP1 x CD3 Bispecific T-cell Engager (XmAb) / Other CancersMetastatic Castration-Resistant Prostate CancerPhase 1 BGB-45035IRAK4 Chimeric Degradation Activation Compound [CDAC] / Immunology & InflammationRheumatoid ArthritisPhase 2Skin DiseasesPhase 1 24assets NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3 ZilebesiranRNAi therapeutic / CardiovascularHypertensionPhase 3REVERSIR HypertensionPhase 1 RapirosiranALN-HSD / HSD / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2 ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / MetabolicDiabetic Kidney DiseasePhase 2 ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / MetabolicType 2 Diabetes MellitusPhase 1 ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / MetabolicObesity & Weight ManagementPhase 1 ALN-PNPALN-PNP / PNP / RNAi therapeutic / MetabolicNon-Alcoholic Fatty Liver Disease (NAFLD)Phase 1 ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / MetabolicDyslipidemiaPhase 1 ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1 Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/OtherMyasthenia GravisPhase 3Geographic AtrophyPhase 3 MivelsiranALN-APP / APP / RNAi therapeutic / NeuroscienceCerebral Amyloid Angiopathy (CAA)Phase 2Alzheimers DiseasePhase 1 ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / NeuroscienceHuntingtons DiseasePhase 1 ALN-5288ALN-5288 / MAPT / RNAi therapeutic / NeuroscienceAlzheimers DiseasePhase 1 ALN-SODALN-SOD / SOD1 / RNAi therapeutic / NeuroscienceSOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1 ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / NeuroscienceParkinsons DiseasePhase 1 Cemdisiran (+Pozelimab)RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 3 ALN-6400ALN-6400 / PLG / RNAi therapeutic / HematologyBleeding DisordersPhase 2 AG-236ALN-TMP / TMP / RNAi therapeutic / HematologyPolycythemia VeraPhase 1 ALN-CFBALN-CFB / CFB / RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 1 Elebsiran (+Tobevibart)RNAi therapeutic / OtherHepatitis D Virus InfectionPhase 2 ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / OtherHepatocellular CarcinomaPhase 1 ALN-4285ALN-4285 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 ALN-4915ALN-4915 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 ALN-F1202ALN-F1202 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 21assets PumitamigPD-L1/VEGF-A / immunomodulator / OncologyMultiple solid tumors
So, for a long time, I didn't do it, and I didn't want to do it, and I thought, I'm not going to take the shortcut
